Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4676 - 4700 of 5367 in total
MRK-409 is a GABA-A receptor agonist .
Experimental
Matched Iupac: … 5-({[7-cyclobutyl-3-(2,6-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]oxy}methyl)-1-methyl-1H …
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Iupac: … N,N-dimethyl-5-({2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl}oxy)pyrimidine-2-carboxamide …
Navoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).
Investigational
Matched Iupac: … (1R,4r)-4-[(1R)-2-[(5S)-6-fluoro-5H-imidazo[4,3-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol …
Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).
Investigational
Matched Iupac: … 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one …
GB1211 is an orally active galectin-3 (Gal-3) inhibitor.
Investigational
Matched Iupac: … 2-[(5-bromopyridin-3-yl)sulfanyl]-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl …
Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair. Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to...
Investigational
Matched Iupac: … ,6R)-5-[(2S,4S,4'aR,5R,5'S,6R,7'R,8'S,8'aS)-5-acetamido-8'-{[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-6- ... (hydroxymethyl)-4-{[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4 ... -hydroxy-7'-(hydroxymethyl)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-hexahydrospiro[oxane-2,2'-pyrano[3,4-b ... ][1,4]dioxin]-3'-oneoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-hydroxyoctadec-4-en-2-yl]octadecanamide …
Experimental
Matched Iupac: … N-[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4R,5R,6S)-5-acetamido-6-{[(2R,3S,4R,5R,6R)-5-acetamido-4,6-dihydroxy-2 ... -(hydroxymethyl)oxan-3-yl]oxy}-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl …
E5531 is an endotoxin antagonist.
Investigational
Matched Iupac: … {[(2R,3S,4R,5R,6R)-4-{[(3R)-3-[(5Z)-dodec-5-enoyloxy]decyl]oxy}-6-{[(2R,3S,4R,5R,6R)-3-hydroxy-4-{[(3R ... )-3-hydroxydecyl]oxy}-5-(3-oxotetradecanamido)-6-(phosphonooxy)oxan-2-yl]methoxy}-2-(methoxymethyl)-5 …
Tildipirosin is a veterinary antibiotic.
Vet approved
Matched Iupac: … (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2- …
Experimental
Matched Iupac: … methyloxan-2-yl]oxy}-4-(formyloxy)-6-methyloxan-2-yl]oxy}-4-(formyloxy)-6-methyloxan-2-yl]oxy}-11-hydroxy ... 5S,7R,10R,11S,13S,14R,15R)-5-{[(2R,4S,5R,6R)-5-{[(2S,4S,5R,6R)-5-{[(2S,4S,5R,6R)-4,5-bis(formyloxy)-6- …
Investigational
Matched Iupac: … methyloxan-2-yl]oxy}oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol ... (2S,3R,4S,5S,6R)-2-{[(2R,3S,4S,5R,6R)-3-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R ... 10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosane-6,2'-piperidin]-18-eneoxy]-5-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6- …
Experimental
Illicit
Matched Iupac: … (1S,2R,5S,10R,11S,14S,15S)-2,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,14-diol …
Experimental
Matched Iupac: … (3aS)-3a-hydroxy-6-methyl-1-phenyl-1H,2H,3H,3aH,4H-pyrrolo[2,3-b]quinolin-4-one …
Experimental
Matched Iupac: … 1-tert-butyl-4-{6-methanesulfonyl-4'-methoxy-2-methyl-[1,1'-biphenyl]-3-carbonyl}-1H-pyrazol-5-ol …
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Iupac: … 4',7'-diazaspiro[piperidine-4,2'-tricyclo[8.4.0.0^{3,7}]tetradecane]-1'(10'),3',5',11',13'-pentaene-6' …
Investigational
Matched Iupac: … N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[(2S)-2,3-dihydroxypropyl]cyclopropane …
S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Investigational
Matched Iupac: … 4-(1,2-oxazol-3-yl)-12-oxa-3,5,8-triazatricyclo[7.4.0.0^{2,6}]trideca-1(9),2(6),3,7-tetraene …
Investigational
Matched Iupac: … 6-(2,4-difluorophenoxy)-8-methyl-2-[(oxan-4-yl)amino]-7H,8H-pyrido[2,3-d]pyrimidin-7-one …
Experimental
Matched Iupac: … [(1R)-6-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}hexyl]boronic …
Experimental
Matched Iupac: … (2S)-1-[4-({6-[(2,5-dichlorophenyl)imino]-1,6-dihydropyrimidin-2-yl}amino)phenoxy]-3-(dimethylamino)propan …
PH-797804 has been investigated for the treatment of Osteoarthritis.
Investigational
Matched Iupac: … 3-{3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1,2-dihydropyridin-1-yl}-N,4-dimethylbenzamide …
Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce blood...
Experimental
Matched Iupac: … 5-{[4-(2-{[6-(4-methoxyphenoxy)pyrimidin-4-yl](methyl)amino}ethoxy)phenyl]methyl}-1,3-thiazolidine-2,4 …
Displaying drugs 4676 - 4700 of 5367 in total